Legend’s target strategy pays off with BCMA CAR T approval

Legend’s decision to take on higher risk targets for its CAR T cell therapies than most of its Chinese peers has paid off with FDA’s approval of its first product, cilta-cel, and the company is applying the same target strategy to the rest of its pipeline. 

By combining new targets and innovative platform technologies with access to certain clinical development opportunities available to Chinese biotechs, Legend is next aiming to address the biggest challenges facing CAR T cell developers: creating off-the-shelf products, and bringing the therapies into solid tumor indications. ...